Veracyte (VCYT) Q2 2026: Prosigna Launch and 20% Decipher Growth Signal Expanding Oncology Franchise

2026-07-30 | By EarningsIQ Research

Veracyte’s Q2 2026 marked a turning point, as the company launched Prosigna LDT and TrueMRD, unlocking new addressable markets in breast and bladder cancer diagnostics while maintaining impressive core growth and margin expansion. The company’s execution on evidence generation, reimbursement, and operational leverage positions it to sustain double-digit growth, even as it accelerates investment in sales and workflow automation to capture mounting demand. With guideline shifts and pipeline readouts ahead, Veracyte’s risk-reward profile is increasingly defined by its ability to scale new launches and deepen penetration across the cancer care continuum.

Summary

• Prosigna and TrueMRD Launches Broaden Oncology Platform: New test introductions expand Veracyte’s reach and strengthen its growth engine.
• Core Franchises Drive Durable Double-Digit Growth: Decipher and Afirma continue to deliver strong volume and pricing leverage.
• Investment in Commercial Scale and Evidence Pipeline: Accelerated salesforce build and robust clinical studies support future expansion.

Business Overview

Veracyte, precision oncology diagnostics, develops and commercializes molecular tests that inform cancer treatment decisions across the care continuum. Its revenue model is driven by testing volume and average selling price (ASP) from its core franchises—Decipher, prostate and bladder cancer risk stratification; Afirma, thyroid nodule diagnostics; Prosigna, breast cancer recurrence risk; TrueMRD, minimal residual disease monitoring—with additional revenue from cytology services. The company’s multi-test portfolio targets high-value clinical inflection points, supported by evidence generation and payer coverage to drive adoption.

Performance Analysis

Q2 2026 demonstrated Veracyte’s ability to scale new product launches while maintaining core momentum and operating leverage. Total revenue grew 15% year-over-year, with total testing volume up 14%, reflecting broad-based demand across Decipher, Afirma, and the initial ramp of Prosigna and TrueMRD. Notably, Decipher revenue rose 20% on 17% volume growth, with improved ASP from payer engagement and operational execution, while Afirma delivered 18% revenue growth on 10% higher volume and continued market share gains.

Gross margin expanded 340 basis points to 74.9%, driven by operational efficiencies, higher ASP, and workflow improvements, particularly in the Afirma V2 transcriptome process. Operating expenses rose 16% as the company accelerated R&D and commercial investment, particularly for new launches. Adjusted EBITDA margin reached 29.2%, well above the long-term target, underscoring the business’s inherent leverage even as Veracyte invests in future growth drivers.

• Decipher ASP Uplift: Operational and market access initiatives yielded sustained pricing gains, offsetting modest volume guidance reduction in low-risk prostate cancer.
• Afirma Workflow Drives Volume: The V2 transcriptome workflow improved reportability and contributed to a 400 basis point lift in test volume.
• Prosigna and TrueMRD Early Traction: Both launches saw strong physician engagement and institutional interest, setting the stage for future revenue inflection pending broader reimbursement and workflow integration.

Cash generation remained robust, with $45.8 million in operating cash flow and a cash balance of $485.2 million, giving Veracyte ample flexibility for pipeline and commercial investment.

Executive Commentary

Strategic Positioning

1. Breast Cancer Franchise Expansion with Prosigna

Prosigna, breast cancer recurrence risk test, is positioned as a foundational pillar following the Optima trial, which delivered level 1A prospective evidence and significant media attention at ASCO. Veracyte is targeting the entire ER-positive, HER2-negative population, not just node-positive patients, and is already engaging over 100 institutions, including major cancer centers. Early feedback indicates potential for broad adoption, with some centers considering full conversion. The company is actively educating key opinion leaders and accelerating salesforce growth to capture demand.

2. TrueMRD Platform Launch and Bladder Cancer Opportunity

TrueMRD, minimal residual disease (MRD) monitoring platform, launched its first test for muscle invasive bladder cancer (MIBC) with Medicare reimbursement. The platform’s whole genome sequencing approach offers a differentiated, extensible technology for longitudinal tumor tracking. Veracyte is leveraging its Decipher brand and urology relationships to drive initial adoption, with further pipeline expansion and evidence generation planned for additional tumor types and indications.

3. Decipher Prostate: Penetration and Evidence-Driven Growth

Decipher, prostate cancer risk stratification test, continued to grow in intermediate and high-risk categories, supported by guideline inclusion and new predictive evidence from trials like Enzimet. Low-risk volume guidance was trimmed due to guideline changes, but Veracyte maintains a 20% revenue growth outlook for Decipher, with ASP gains offsetting volume adjustments. The company sees a long runway for penetration, particularly as new studies in low-risk and active surveillance populations read out over the next few years.

4. Afirma Thyroid Franchise: Operational and Evidence Momentum

Afirma, thyroid nodule molecular diagnostic, posted strong volume and share gains, underpinned by workflow enhancements and expanding clinical evidence. The V2 transcriptome workflow has improved no-result rates, while the Afirma Grid program is fostering new academic and industry collaborations, fueling a virtuous cycle of evidence generation and market leadership.

5. Commercial Scale and Workflow Integration

Veracyte is investing in salesforce expansion and EMR integration to support Prosigna and TrueMRD adoption, recognizing that workflow automation is critical for scaling in high-volume centers. The company is leveraging existing infrastructure from Decipher and Afirma to accelerate onboarding and streamline test ordering, aiming to minimize logistical friction for physicians and administrators.

Key Considerations

Veracyte’s Q2 2026 results reflect a company balancing disciplined execution in its legacy franchises with bold investment in new growth vectors. The company’s ability to scale new launches, drive pricing leverage, and maintain operating discipline will be critical as it seeks to expand its addressable markets and defend its leadership in precision oncology diagnostics.

Key Considerations:

• Prosigna Adoption Pace: Early institutional interest and broad guideline evidence could drive rapid market share gains if reimbursement and workflow hurdles are cleared.
• Decipher Low-Risk Trajectory: Guideline changes have tempered near-term growth in low-risk prostate, but multiple ongoing studies could unlock this large untapped segment by 2027–2029.
• TrueMRD Platform Scaling: The initial MIBC launch is a proof point, but broader MRD opportunity depends on evidence, reimbursement, and operational scalability across new tumor types.
• Operating Leverage vs. Investment: Margin expansion and cash flow remain strong, but management is clear-eyed about reinvesting in sales, automation, and R&D to sustain future growth.
• Evidence Generation as Moat: Robust publication pipeline and real-world data underpin franchise durability and future guideline inclusion, especially in contested or evolving indications.

Risks

Key risks include reimbursement timing for new launches, particularly Prosigna LDT’s transition to centralized testing and pending Moldiacs review, as well as the pace of EMR integration and workflow adoption. Guideline volatility, especially in prostate low-risk, could constrain growth until new evidence matures. Competitive threats from AI-based diagnostics remain limited for now, but the landscape is evolving. Investor attention should remain on execution in new launches and the durability of core franchise growth.

Forward Outlook

For Q3 and Q4 2026, Veracyte guided to:

• Decipher volume of approximately 31,000 tests in Q3 and 33,000 in Q4
• Afirma volume expected to step down slightly in Q3, with a larger sequential step up in Q4

For full-year 2026, management raised guidance:

• Total revenue of $590–$596 million (14–15% YoY growth)
• Testing revenue of $576–$582 million (17–18% YoY growth)
• Decipher revenue growth of approximately 20%
• Afirma revenue growth of 12–14%
• Adjusted EBITDA margin of greater than 26%

Management emphasized continued investment in commercial scale and evidence generation, with ASP expected to remain slightly higher than 2025 and PPCs contributing to outperformance year-to-date. Revenue guidance excludes contribution from Prosigna LDT pending Medicare reimbursement.

• Focus on scaling Prosigna and TrueMRD launches
• Anticipated clinical readouts and pipeline progress in low-risk prostate and additional MRD indications

Takeaways

Veracyte’s Q2 2026 results reinforce its position as a leader in precision oncology diagnostics, with robust core growth and the early success of new test launches. The company’s disciplined capital allocation, focus on evidence generation, and operational leverage provide a strong foundation for continued expansion.

• Launch Execution: Prosigna and TrueMRD launches have broadened Veracyte’s commercial and clinical footprint, with early adoption signals and robust institutional engagement.
• Core Franchise Resilience: Decipher and Afirma continued to deliver double-digit growth and margin expansion, offsetting pockets of guideline-driven volume softness.
• Future Growth Catalysts: Investors should watch for reimbursement milestones, evidence readouts in low-risk prostate and MRD, and the pace of commercial scaling in new indications.

Conclusion

Veracyte’s Q2 showcased the company’s ability to execute on both core and emerging growth drivers, with operational discipline and strategic investment underpinning a robust outlook. The next phase will test Veracyte’s capacity to scale new launches and convert strong clinical evidence into durable commercial leadership.

Industry Read-Through

Veracyte’s experience highlights the growing importance of rigorous clinical evidence and workflow integration in oncology diagnostics. The rapid adoption of Prosigna following Optima, and the operational focus on EMR integration, point to rising expectations for real-world utility and seamless practice integration. Competitors in molecular diagnostics must prioritize evidence generation and payer engagement, as guideline changes can swiftly alter growth trajectories. The expanding MRD market, with its emphasis on whole genome approaches and longitudinal monitoring, signals a shift toward more comprehensive, scalable cancer surveillance solutions. Sector-wide, the bar for clinical and operational differentiation is rising, favoring platforms that can deliver both robust evidence and scalable adoption.

VCYT Healthcare Diagnostics Oncology Precision Medicine Evidence Generation Reimbursement Workflow Automation